Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Open access
Weil, Marcie K., Chen, Alice P. · 2011 · Current Problems in Cancer

Abstract

DNA damages result from errors in replication, production of reactive oxygen species, and exposure to ultraviolet rays and ionizing radiation. These lesions that result from these noxious events include point mutations, single strand breaks (SSBs), double strand breaks (DSBs), intrastrand and interstrand cross-links. Cells employ multiple types of DNA repair mechanisms: base excision repair (BER), nucleic acid excision repair (NER), homologous recombination(HR), single strand annealing (SSA), Mismatch Repair (MMR), and nonhomologous end joining (NHEJ) to repair these damages on a regular basis. As a result of DNA repair, injured cells can survive, which is optimal for normal cells, but exactly the opposite of the goal for tumor cells that undergo DNA damage in response to chemotherapy or radiation. In addition, errors can occur in the repair process especially with NHEJ that can lead to new abnormalities and dysfunction of the cells. Certain genetic disorders, such as BRCA1 and BRCA2 mutations, as well as other genetic anomalies that prevent DNA repair are associated with increased risk of malignancies. [3] PARP is a family of proteins with enzymatic properties, scaffolding properties, and recruiting ability for other necessary DNA repair proteins. [4] PARP 1 and PARP 2 are the best known of these proteins and are critical for the function of BER. BER repairs single strand DNA breaks and inhibition of BER may ultimately lead to cell death. This makes PARP proteins ideal targets for anticancer therapy. PARP inhibitors interfere with BER and therefore DNA repair. By this route, PARP inhibitors can affect death of tumor cells. PARP inhibitors currently under clinical development are targeted to PARP 1 and PARP 2 proteins. They include Pfizer’s PF 01367338 (AG014699), AstraZeneca’s olaparib (AZD2281, KU-0059436), sanofi-aventis’ iniparib (BSI 201), Abbott Laboratories’ veliparib (ABT 888), Merck’s MK 4827, and Cephalon’s CEP 9722. Biomarin’s BMN673 (LT-673) and BiPar Science’s BSI 401 are in preclinical development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.currproblcancer.2010.12.002

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 162

Metadata

Authors
Weil, M. K., & Chen, A. P.
Venue
Current Problems in Cancer
Publisher
Elsevier BV
Published
2011-01
Volume
35
Issue
1
Pages
7-50
ISSN
0147-0272 (ISSN-L)
OpenAlex
W2018691707
Cited by
162
References
12
FWCI
4.41
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PARP Inhibitor Treatment in Ovarian and Breast Cancer. https://app.cochat.ai/papers/10.1016/j.currproblcancer.2010.12.002
The paper
Weil, M. K., & Chen, A. P. (2011). PARP Inhibitor Treatment in Ovarian and Breast Cancer. Current Problems in Cancer. https://doi.org/10.1016/j.currproblcancer.2010.12.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.